NAT COMMUN:中国科学家发现新的抗乙肝病毒基因

2016-06-13 沈基飞 刘洪亮 中新社

解放军军事医学科学院放射与辐射医学研究所周钢桥研究员团队牵头联合国内多家科研机构,从遗传学、病毒学、功能和分子机制等多个角度,首次发现一种“整合因子复合体”基因INTS10可激活人体先天性免疫功能,发挥抑制乙肝病毒复制的作用。这一研究成果揭示了“整合因子复合体”具有此前从未被发现的抑制病原微生物感染的新作用,为其研究开辟了新的方向。同时,有助于深入了解乙肝病毒慢性感染的分子机制,为有效防治提供了理

解放军军事医学科学院放射与辐射医学研究所周钢桥研究员团队牵头联合国内多家科研机构,从遗传学、病毒学、功能和分子机制等多个角度,首次发现一种“整合因子复合体”基因INTS10可激活人体先天性免疫功能,发挥抑制乙肝病毒复制的作用。

这一研究成果揭示了“整合因子复合体”具有此前从未被发现的抑制病原微生物感染的新作用,为其研究开辟了新的方向。同时,有助于深入了解乙肝病毒慢性感染的分子机制,为有效防治提供了理论依据和新的候选生物靶标。这一研究成果日前发表在《自然·通讯》杂志上。

目前中国约有1.2亿名乙肝病毒慢性携带者,预防和治疗慢性乙肝涉及国计民生。为了发现与乙肝病毒慢性感染相关的易感基因或抗性基因,周钢桥科研团队牵头联合广西医科大学、南京医科大学和中山大学等机构的研究人员,汇集了10000余例全基因组分型数据,从中筛选出1251例乙肝病毒慢性感染者和1057例已自然清除乙肝病毒感染的对照个体,系统比较了两组的遗传学差异。随后,又在来自国内其他4个地区的共计3905例感染者和3356例对照个体中,对这些遗传差异进行了大规模验证,最终在染色体8p21.3位置发现了一个全新的与乙肝病毒感染相关的基因区域。进一步的功能研究显示,该区域的INTS10基因能够激活细胞内RIG-I样受体通路中的关键分子IRF3,并显著促进III型干扰素的表达,最终发挥抑制乙肝病毒复制的功能。

“整合因子复合体”是一种多功能蛋白质复合物,由至少12个成员组成,能够介导核糖核酸的加工,进而在基因组损伤应答、肿瘤的发生发展等方面发挥重要作用。但是,以往未发现整合因子复合体成员在病原微生物感染致病过程中发挥作用,因此,这项研究首次发现该复合体具有一种此前未知的新功能,从而为整合因子复合体的研究以及病原微生物的感染机制研究提供了新的视角。众所周知,干扰素诱发的免疫反应是抵御乙肝病毒感染的关键,但是以往的研究主要集中在机体免疫细胞分泌的I型、II型干扰素上。这项研究发现肝细胞本身具有分泌III型干扰素进而发挥抑制乙肝病毒复制的作用,从而为III型干扰素治疗慢性乙肝提供了新的理论依据。

原始出处

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086868, encodeId=572f208686894, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 07 22:27:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024250, encodeId=4b53202425036, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Dec 14 14:27:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802328, encodeId=b0b7180232859, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Feb 04 15:27:00 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881112, encodeId=93a7188111229, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 29 00:27:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516911, encodeId=f8221516911c0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Wed Jun 15 12:27:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
    2016-07-07 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2086868, encodeId=572f208686894, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 07 22:27:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024250, encodeId=4b53202425036, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Dec 14 14:27:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802328, encodeId=b0b7180232859, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Feb 04 15:27:00 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881112, encodeId=93a7188111229, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 29 00:27:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516911, encodeId=f8221516911c0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Wed Jun 15 12:27:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2086868, encodeId=572f208686894, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 07 22:27:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024250, encodeId=4b53202425036, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Dec 14 14:27:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802328, encodeId=b0b7180232859, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Feb 04 15:27:00 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881112, encodeId=93a7188111229, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 29 00:27:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516911, encodeId=f8221516911c0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Wed Jun 15 12:27:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2086868, encodeId=572f208686894, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 07 22:27:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024250, encodeId=4b53202425036, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Dec 14 14:27:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802328, encodeId=b0b7180232859, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Feb 04 15:27:00 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881112, encodeId=93a7188111229, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 29 00:27:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516911, encodeId=f8221516911c0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Wed Jun 15 12:27:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]
    2016-10-29 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=2086868, encodeId=572f208686894, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 07 22:27:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024250, encodeId=4b53202425036, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Wed Dec 14 14:27:00 CST 2016, time=2016-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802328, encodeId=b0b7180232859, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Sat Feb 04 15:27:00 CST 2017, time=2017-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881112, encodeId=93a7188111229, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sat Oct 29 00:27:00 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516911, encodeId=f8221516911c0, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Wed Jun 15 12:27:00 CST 2016, time=2016-06-15, status=1, ipAttribution=)]

相关资讯

EASL 2016:REP 2139治疗HBV/HDV合并感染有疗效

根据2015 AASLD会议上一项小型2期临床试验的研究结果显示,核苷酸聚合物REP 2139,首先单一疗法,然后结合聚乙二醇干扰素,能够降低乙型肝炎表面抗原(HBsAg)水平,降低丙型肝炎病毒载量,并增加抗-HBs 抗体效价。研究对象被分成2个不同的组,其中一半为部分应答,一半为完全应答。2016 欧洲肝病学会学术年会上, 加拿大 Replicor 公司等机构的科研人员联合发布一项有关

慢性乙肝一线治疗药物替诺福韦酯等大降价

对专利药品、独家生产药品,建立公开透明、多方参与的药品价格谈判机制,是深化医药卫生体制改革、推进公立医院药品集中采购、降低广大患者用药负担的重要举措。2016年5月20日,首批国家药品价格谈判结果向社会公布,其中有慢性乙肝一线治疗药物替诺福韦酯,非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼。与之前公立医院的采购价格比较,3种谈判药品价格降幅均在50%以上,与周边国家(地区)趋同。 2015年10月

Am J Gastroenterol:他汀类药物可降低乙肝患者肝硬化风险

研究者进行了一项研究,探究他汀类药物对慢性乙型肝炎发展为肝硬化和失代偿的保护作用。台湾国泰综合医院医学中心肝病中心的Yi-Wen Huang博士和同事对1997年至2009年台湾健康保险研究数据库的298,761名慢性HBV患者的数据进行了分析。其中有6,543名患者使用他汀类药物,按1:1匹配未使用他汀类药物的对照组。研究者对参与者进行随访,随访时间从开始使用他汀类药物,直到发展为肝硬化失代偿或

ALIMENT PHARM THERAP:乙肝病毒感染清除后,患肝癌风险仍较大!

乙型病毒性肝炎由乙肝病毒(HBV)引起,以乏力、食欲减退、恶心、呕吐、厌油、肝大及肝功能异常为主要临床表现,通过体液如性交、共用针头和其他注射设备及母婴传播等方式进行传播。CDC指出,慢性乙肝的风险是与年龄相关的;受感染的婴儿中90%成为慢性感染者,而成人中仅有2-6%为慢性感染者。 自1991年以来,美国作为第一个制定措施消除乙型肝炎病毒感染的国家,并为2儿童进行常规疫苗接种,由此,婴儿感染乙肝

一款乙肝神药有望面世,血清病毒水平可降低99.99%

 近日,乙肝药物领域风云再起,美国生物技术公司Arrowhead (NASDAQ:ARWR) 发布旗下乙肝候选药物ARC-520 临床IIb期积极数据,通过与百时美施贵宝(BMS)乙肝药Baraclude (entecavir)联合,用于治疗难治性HBeAg阴性慢性乙型肝炎患者。结果显示,ARC-520+Baraclude治疗组,患者血清HBV DNA水平可显著降低9

PLOS ONE:NAPs 用于HBeAg阳性慢乙肝患者效果良好

先前的体内研究显示核酸聚合物 (NAPs)或能通过阻断感染乙肝病毒的肝细胞的 HBsAg 释放从而降低血液中循环中的 HBsAg ,而这一抑制病毒蛋白释放的机制或能获得临床获益。来自班加班谢赫穆吉布医科大学(Bangabandhu Sheikh Mujib Medical University)和 Replicor 公司的研究人员共同发布了一项有关核酸聚合物 (NAPs)用于 HBeAg 阳性慢乙